#AVID100 - Twitter Hashtag

almost 7 years ago

Meet us @World_ADC in San Diego! Our CSO, Maureen O'Connor, will give an invited talk on #AVID100 - our novel #EGFR #ADC in Phase 2 development in #HNSCC, #TNBC and #NSCLC. #biotech #pharmaceuticals #Austin #Montreal #SanDiego #worldADC

Forbius_'s tweet photo. Meet us @World_ADC in San Diego! Our CSO, Maureen O'Connor, will give an invited talk on #AVID100 - our novel #EGFR #ADC in Phase 2 development in #HNSCC, #TNBC and #NSCLC. #biotech #pharmaceuticals #Austin #Montreal #SanDiego #worldADC https://t.co/4JOUHE53SU

0

2

1

0

Forbius @Forbius_

over 7 years ago

Forbius' AVID100, a Novel Anti-EGFR ADC, Cleared by Health Canada to Commence Phase 2 Clinical Trials in EGFR-overexpressing SCCHN, NSCLC and TNBC: https://t.co/kBreqAAV3p #Forbius #ClinicalTrial #AVID100 #HealthCanada #Austin #Texas #Montreal #Quebec #Phase2 #News

0

3

1

0

Forbius @Forbius_

over 7 years ago

@Forbius_ Announces First Patient Dosed in Phase 2a Triple Negative Breast Cancer (TNBC) Trial of AVID100, a Novel, Tumor-Selective Anti-EGFR ADC: https://t.co/bvtLIyp0Fy #Forbius #AVID100 #Austin #Texas #Quebec #Montreal #ClinicalTrials #ClinicalStudies #TNBC #AntiEGFR

Forbius_'s tweet photo. @Forbius_ Announces First Patient Dosed in Phase 2a Triple Negative Breast Cancer (TNBC) Trial of AVID100, a Novel, Tumor-Selective Anti-EGFR ADC: https://t.co/bvtLIyp0Fy

#Forbius #AVID100 #Austin #Texas #Quebec #Montreal #ClinicalTrials #ClinicalStudies #TNBC #AntiEGFR https://t.co/F8jotfp48N

0

1

0

Forbius @Forbius_

over 7 years ago

Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing https://t.co/x99Sm9OPuC #Forbius #ClinicalTrial #AVID100 #EGFR #ADC #AARC2019

Forbius_'s tweet photo. Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing

https://t.co/x99Sm9OPuC

#Forbius #ClinicalTrial #AVID100 #EGFR #ADC #AARC2019 https://t.co/JvjvCqUzAx

0

5

1

0

Forbius @Forbius_

over 7 years ago

Forbius Announces First Patient Dosed in Phase 2a Squamous Cell Carcinoma of the Head and Neck (SCCHN) Trial of AVID100, a Novel Anti-EGFR ADC: https://t.co/iYE79Vfee4 #Forbius #SSCHN #ClinicalTrial #AVID100 #Austin #Montreal #Phase2a

0

1

0

Forbius @Forbius_

almost 8 years ago

AVID100 Featured in an Invited Oral Presentation at the 9th Annual @World_ADC Summit: https://t.co/Pp5S9WE6zY #Forbius #AVID100 #Presentation #Summit

0

2

1

0

Forbius @Forbius_

almost 8 years ago

AVID200’s Ability to Enhance Anti-tumor T-cell Activity and Promote Sensitivity to PD1 Blockade is Featured in a Poster Presentation at the 2018 @BioCanRx Summit for Cancer Immunotherapy: https://t.co/opLYsuxyWP #Forbius #AVID200 #AVID100 #BioCanRX #Presentation

0

4

1

0

Forbius @Forbius_

almost 8 years ago

@ForbiusRX Announces First Patient Dosed in Phase 2 Trial of anti-EGFR ADC AVID100 in EGFR- Overexpressing Squamous NSCLC #Forbius #AVID100 #Phase2Trial #ClinicalTrial https://t.co/GZoE8Pv0Ci

0

2

0

Forbius @Forbius_

almost 8 years ago

Forbius Announces First Patient Dosed in Phase 2 Trial of anti-EGFR ADC AVID100 in EGFR-Overexpressing Squamous NSCLC: https://t.co/zNtNBp6w5H #Forbius #AVID100 #ClinicalTrials

0

3

2

0

Forbius @Forbius_

almost 8 years ago

Forbius Nominated for “Best New Drug Developer” Award for the 2018 @World_ADC Awards: https://t.co/yOb4dBgWuY #Honored #Forbius #AVID100 #AVID200 #Nomination #WorldADC #Award

0

1

0

Forbius @Forbius_

about 8 years ago

We're honored to announce that Forbius (Formation Biologics) was awarded an $18.8 Million Grant by the Cancer Prevention and Research Institute of Texas (@CPRITTexas): https://t.co/TWftrLELQN #Forbius #CPRIT #AVID100

0

5

1

0

Top Tweets for #AVID100

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users